IRIS
CIANI, ORIANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.376
NA - Nord America 3.908
AS - Asia 1.432
SA - Sud America 24
Continente sconosciuto - Info sul continente non disponibili 19
OC - Oceania 18
AF - Africa 11
Totale 10.788
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.682
IT - Italia 2.376
IE - Irlanda 1.099
CN - Cina 494
GB - Regno Unito 450
UA - Ucraina 417
DE - Germania 254
SE - Svezia 223
CA - Canada 222
SG - Singapore 198
TR - Turchia 196
FI - Finlandia 182
HK - Hong Kong 148
VN - Vietnam 144
FR - Francia 78
KR - Corea 75
BG - Bulgaria 54
IN - India 54
CZ - Repubblica Ceca 52
KZ - Kazakistan 48
BE - Belgio 33
NL - Olanda 22
ES - Italia 20
RO - Romania 20
IR - Iran 18
EU - Europa 17
AU - Australia 16
CH - Svizzera 13
PT - Portogallo 11
AT - Austria 10
DK - Danimarca 10
BR - Brasile 9
JP - Giappone 9
PL - Polonia 9
AE - Emirati Arabi Uniti 8
NO - Norvegia 7
RU - Federazione Russa 6
LV - Lettonia 5
PE - Perù 5
PH - Filippine 5
CL - Cile 4
GR - Grecia 4
HU - Ungheria 4
IL - Israele 4
LT - Lituania 4
LU - Lussemburgo 4
PK - Pakistan 4
EC - Ecuador 3
TH - Thailandia 3
AL - Albania 2
AZ - Azerbaigian 2
CO - Colombia 2
EG - Egitto 2
GE - Georgia 2
ID - Indonesia 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
MA - Marocco 2
MX - Messico 2
NZ - Nuova Zelanda 2
OM - Oman 2
PA - Panama 2
SK - Slovacchia (Repubblica Slovacca) 2
TJ - Tagikistan 2
UZ - Uzbekistan 2
ZA - Sudafrica 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AD - Andorra 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
BY - Bielorussia 1
CD - Congo 1
CM - Camerun 1
EE - Estonia 1
GH - Ghana 1
KE - Kenya 1
KH - Cambogia 1
LK - Sri Lanka 1
MO - Macao, regione amministrativa speciale della Cina 1
MY - Malesia 1
NG - Nigeria 1
PS - Palestinian Territory 1
PY - Paraguay 1
SA - Arabia Saudita 1
SM - San Marino 1
TW - Taiwan 1
Totale 10.788
Salva come PNG Salva come JPEG
Città #
Dublin 1.095
Chandler 673
Milan 517
Jacksonville 334
Ann Arbor 258
Southend 215
Toronto 186
Rome 173
Redmond 149
Hong Kong 147
Dearborn 146
New York 145
Beijing 137
Dong Ket 130
Helsinki 120
Singapore 118
Wilmington 116
Houston 111
Ashburn 105
Lawrence 97
Modena 92
Boston 90
Boardman 84
Seoul 71
Izmir 68
Redwood City 50
Almaty 48
Mountain View 48
Palombara Sabina 47
Naples 46
Los Angeles 45
Seattle 41
Woodbridge 40
Fairfield 36
Bologna 31
Frankfurt am Main 31
Brussels 29
Fremont 27
Bari 25
Turin 24
Ottawa 22
Brno 20
Florence 20
Catania 19
Munich 19
Washington 18
Bucharest 16
Hefei 16
Kunming 15
Nanjing 15
West Jordan 15
Guangzhou 14
Lappeenranta 14
Chennai 13
Dallas 13
Jinan 13
Palermo 13
Trieste 13
Robbiate 12
Napoli 11
Trento 11
Bonndorf 10
Falls Church 10
Norwalk 10
Shenyang 10
Torino 10
Darwin 9
Monza 9
Nardò 9
Nuremberg 9
Amsterdam 8
Bergamo 8
Genoa 8
Padova 8
Verona 8
Vienna 8
Ardabil 7
Auburn Hills 7
Carrara 7
Cesa 7
Lisbon 7
Livorno 7
London 7
Messina 7
Monmouth Junction 7
Perugia 7
Riposto 7
Cento 6
Crotone 6
Desenzano Del Garda 6
Forlì 6
Nanchang 6
Novara 6
Olomouc 6
Pavia 6
Pomezia 6
Reggio Emilia 6
Santa Clara 6
Taranto 6
Tokyo 6
Totale 6.556
Salva come PNG Salva come JPEG
Nome #
La funzione di HTA nelle aziende sanitarie italiane: un potenziale ancora inutilizzato? 310
Prezzi di riferimento per dispositivi medici: criticità, vantaggi e approcci 289
Esiti di salute e performance del Servizio Sanitario Nazionale 265
PDTA per la chirurgia bariatrica: l'esperienza di 6 centri italiani 253
I dispositivi medici in Italia: un settore, tanti mercati 214
Dinamiche economiche e performance del settore dei dispositivi medici in Italia 212
Programma nazionale HTA per dispositivi medici: quali sfide per l’implementazione? 198
EQ-5D-5L population norms for Italy 173
Gli esiti di salute del Servizio Sanitario Nazionale 166
Current and Future Trends in the HTA of Medical Devices 154
De innovatione: the concept of innovation for medical technologies and its implications for healthcare policy-making 154
Real-world data for the evaluation of transarterial radioembolization versus sorafenib in hepatocellular carcinoma: a cost-effectiveness analysis 152
Gli esiti di salute del Servizio Sanitario Nazionale 146
La dimensione del settore dei dispositivi medici 143
Myth #5: health care is rightly left to the private sector, for the sake of efficiency 143
Exercise-based cardiac rehabilitation for chronic heart failure: the EXTRAMATCH II individual participant data meta-analysis 143
Endpoint surrogati e politiche sanitarie: l’importanza di metodi di validazione adeguati 138
The Lung Cancer App (LuCApp) study protocol: a randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer 130
An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration 128
Surrogate endpoints in health technology assessment: an international review of methodological guidelines 124
A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer 122
Integrating HTA principles into procurement of medical devices: the Italian national HTA programme for medical devices 122
Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses 116
Patient-reported outcome measures in core outcome sets targeted overlapping domains but through different instruments 114
I processi di valutazione dei dispositivi medici e delle tecnologie sanitarie 111
Comparing drug and non-drug technologies in comparative effectiveness research 109
Valutare l’impatto dell’HTA come strumento di governo dell’innovazione tecnologica: modelli teorici e studi empirici 109
Measuring value in health care: a comparative analysis of value-based frameworks 108
Core outcome set in surgical oncology: why, what and how to measure 108
An economic perspective on urinary tract infection: the "costs of resignation" 106
Mud-bath therapy in addition to usual care in bilateral knee osteoarthritis: economic evaluation alongside a randomized controlled trial 106
A bias-adjusted evidence synthesis of RCT and observational data: the case of total hip replacement 103
Cost–effectiveness analysis of treatments involving radioembolization in intermediate-stage hepatocellular carcinoma 103
Establishing a national HTA program for medical devices in Italy: overhauling a fragmented system to ensure value and equal access to new medical technologies 102
A scoping review of core outcome sets and their 'mapping' onto real-world data using prostate cancer as a case study 101
Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis 100
Diffusion and use of Health Technology Assessment in policy making: what lessons for decentralised healthcare systems? 100
European diabetes research and its funding, 2002–2013 99
Distinguishing features in the assessment of mHealth apps 99
Il settore dei dispositivi medici in Italia. L’impatto delle politiche pubbliche sulle performance delle imprese 97
The rise of rules: will the new regulation of medical devices make us safer? 96
Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study 95
Exercise training for chronic heart failure (ExTraMATCH II): why all data are not equal 94
Combining tumour response and progression free survival as surrogate endpoints for overall survival in advanced colorectal cancer 94
Hospital-based HTA: quale valore per la valutazione delle tecnologie nelle Aziende Sanitarie italiane? 93
Time to review the role of surrogate end points in health policy: state of the art and the way forward 91
Determinants of demand for total hip and and knee arthroplasty: a systematic literature review 89
Complete cytogenetic response and major molecular response as surrogate outcomes for overall survival in first-line treatment of chronic myelogenous leukemia: a case study for technology appraisal on the basis of surrogate outcomes evidence 89
Introduction to economic evaluation and health technology assessment 88
La gestione dell'innovazione tecnologica in sanità: analisi e confronto di alcune politiche regionali in Italia 87
Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological study 87
Decision uncertainty and value of further research: a case-study in fenestrated endovascular aneurysm repair for complex abdominal aortic aneurysms 87
Broadening the concept of value: a scoping review on the option value of medical technologies 87
Harnessing digital health technologies during and after the COVID-19 pandemic: context matters 85
An electronic patient-reported outcome mobile app for data collection in type a hemophilia: design and usability study 85
The evaluation of medical devices: are we getting closer to solve the puzzle? A review of recent trends 84
Health technology assessment methods guidelines for medical devices: how can we address the gaps? the international federation of medical and biological engineering perspective 84
The impacts of diabetes research from 31 European Countries in 2002 to 2013 84
Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework 83
Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections: a European multicentre nested case-control study 81
Non-communicable diseases: mapping research funding organisations, funding mechanisms and research practices in Italy and Germany 81
Esiti di salute e performance del Servizio Sanitario Nazionale 81
Cost-effectiveness analysis of oral nutritional supplements with nutritional counselling in head and neck cancer patients undergoing radiotherapy. 81
Development features and study characteristics of mobile health apps in the management of chronic conditions: a systematic review of randomised trials 81
A more evidence based approach to the use of surrogate end points in policy making 80
Validation of exercise capacity as a surrogate endpoint in exercise-based rehabilitation for heart failure: a meta-analysis of randomized controlled trials 80
A randomized, open-label, multicenter study of the efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate versus dimethyl sulfoxide in women with bladder pain syndrome/interstitial cystitis 79
Value-based healthcare: il nuovo approccio di AIFA alla determinazione multidimensionale del valore 79
Urinary Tract Infections – An Economic Issue 78
Response to COVID-19: was Italy (un)prepared? 78
Do existing real-world data sources generate suitable evidence for the HTA of medical devices in Europe? Mapping and critical appraisal 78
Coverage with evidence development for medical devices in Europe: can practice meet theory? 78
Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer 77
Quantitative body movement and gesture assessment in ergonomics. 76
Validation of surrogate end points for overall survival in advanced colorectal cancer: a harmonized approach is needed 75
Surrogate, friend or foe? The need for case studies of the use of surrogate outcomes in cost-effectiveness analyses 75
Assessment of nonfatal myocardial infarction as a surrogate for all-cause and cardiovascular mortality in treatment or prevention of coronary artery disease: a meta-analysis of randomized clinical trials 75
Health technology assessment of medical devices: a survey of non-European union agencies 74
Exercise training for chronic heart failure (ExTraMATCH II): protocol for an individual participant data meta-analysis 71
Recommendations for developing a lifecycle, multidimensional assessment framework for mobile medical apps 71
Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges 70
Corona-regionalism? Differences in regional responses to COVID-19 in Italy 70
Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers 68
Linking the regulatory and reimbursement processes for medical devices: the need for integrated assessments 68
Impact of exercise-based cardiac rehabilitation in patients with heart failure (ExTraMATCH II) on mortality and hospitalisation: an individual patient data meta-analysis of randomised trials 68
The role of health technology assessment bodies in shaping drug development 65
Value lies in the eye of the patients: the why, what, and how of patient-reported outcomes measures 65
Pervasive technology in Neonatal Intensive Care Unit: a prototype for newborns unobtrusive monitoring 63
A call for better reporting of trials using surrogate primary endpoints 57
Valorizzare gli esiti riferiti dal paziente : opportunità e sfide 55
Esiti di salute e performance del Servizio Sanitario Nazionale 52
Lifecycle evidence requirements for high-risk implantable medical devices: a European perspective 50
Impact of exercise rehabilitation on exercise capacity and quality-of-life in heart failure: individual participant meta-analysis 50
Commentary: Nothing but a toothbrush for beginning the reduction of the postoperative costs in thoracic surgery 48
Validity of surrogate endpoints and their impact on coverage recommendations: a retrospective analysis across international Health Technology Assessment agencies 48
The importance of using the appropriate model for systematic reviews and meta-analyses-reply 48
Editorial: Near-infrared fluorescence guided surgery: state of the evidence from a health technology assessment perspective 46
Quo vadis HTA for medical devices in Central and Eastern Europe? Recommendations to address methodological challenges 44
Lung cancer stage distribution from before COVID-19 through 18 months of the pandemic: the experience of a large-volume oncological referral centre 44
Development of a framework and decision tool for the evaluation of health technologies based on surrogate endpoint evidence 43
Totale 10.203
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.345
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.345
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.449 0 0 84 64 124 246 245 134 153 220 39 140
2020/20211.350 59 86 33 106 143 91 129 58 156 118 116 255
2021/20221.500 107 220 50 68 140 66 58 233 72 145 143 198
2022/20233.178 202 173 86 266 203 223 83 162 1.398 121 161 100
2023/20242.436 109 142 149 59 258 287 193 324 98 180 303 334
2024/2025179 108 71 0 0 0 0 0 0 0 0 0 0
Totale 11.172